VICTORION-ASCERTAIN: Implementation Study (v-ASCERTAIN)

NATerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions
Atherosclerotic Cardiovascular Disease (ASCVD)Coronary Heart Disease (CHD)Cerebrovascular DiseasePeripheral Arterial Disease (PAD)
Interventions
OTHER

SMS messages

Participants will receive monthly SMS messages regarding cardiovascular health (low touch engagement nudges)

OTHER

Telephone-based support calls

Participants will receive telephone-based support calls from a study nurse trained in motivational interviewing. These telephone calls will cover diet, exercise, medication, and where necessary smoking cessation. A summary of any recommendations will then be sent to the primary care physician via email or letter.

OTHER

GP Education

Education of GPs on the European Society of Cardiology (ESC) guidelines and Guideline Directed Management Therapy

Trial Locations (1)

3107

Manningham General Practice, 200 High St, Templestowe Lower, Melbourne

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Monash University

OTHER